Espinoza M, Muiquith M, Lim M, Zhu H, et al. Disease etiology and outcomes after atezolizumab plus bevacizumab in hepatocellular carcinoma: Post-hoc analysis of IMbrave150. Gastroenterology 2023 Mar 7:S0016-5085(23)00234.
PMID: 36894034